Generex Biotech (GNBT) Receives $800K in Initial Purchase Orders for Crave-NX Diet Spray
More News related to GNBT
- Generex Oral-lyn(TM) Presentation at CODHy Congress
- Market Watch for Generex Biotechnology Corp. Issued by StockPreacher
- Generex Receives Positive Responses From Independent Physicians and Nurse Practitioners in Recent Focus Groups Conducted in the United States for Generex Oral-lyn(TM)
- Generex Biotech (GNBT) Announces Development of Key Strategic Distribution Relationships for Oral-Lyn
- Generex Establishes Key Strategic Relationships for the Development of a Distribution Network for Generex Oral-lyn(R) Under the FDA's Expanded Access Treatment IND Program
Generex Biotechnology Corporation (NASDAQ: GNBT) today announced that it has thus far received an aggregate of over $800,000 in initial purchase orders for the Company's proprietary Crave-NX 7-Day Diet Aid Spray. These initial orders come as part of the Company's agreement announced earlier this week with a major nationwide pharmacy chain to market the Company's Crave-NX 7-Day Diet Aid Spray throughout the pharmacy's nationwide network of over 7,000 stores.
Related Categories
Corporate NewsStocks Mentioned
-0.05Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
